Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview

Surface Oncology

28/07/2023 14:52

* Surface Oncology Inc  SURF.OQ   SURF.O  is expected
to show no
change in quarterly revenue when it reports  results on August 1
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Surface Oncology
Inc is
for a loss of 34 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Surface
Oncology
Inc is $1.15​, above​ its last closing price of $0.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.35       -0.36      -0.33     Beat    8.3
 Dec. 31 2023              -0.33      -0.35     Missed  -6.1
 Sep. 30 2022  -0.47       -0.47      -0.39     Beat    16.4​
 Jun. 30 2022  -0.47       -0.46      -0.46     Met     -0.4
 ​​Mar.        -0.28       -0.28      0.13      Beat    145.6
 31 2022                                                
 Dec. 31 2021  -0.15       -0.15      -0.52     Missed  -242.8
                                                        ​
 Sep. 30 2021  -0.40       -0.40      -0.44     Missed  -9.1
 Jun. 30 2021  -0.35       -0.35      -0.44     Missed  -24.5
 This summary was machine generated July 28 at 13:52 GMT.  All
figures in US dollars  unless otherwise stated